CTLA4 and pancreatic adenocarcinoma: Based on the above analysis of immune characteristics and tumor microenvironment in the high and low risk group of PAAD patients, we further investigated the differences of CD274 and CTLA4, two important immune checkpoint molecules, between the high and low risk groups.